LaCava Research Wiki

Initiated September 2017

Feb. 19, 2020 - SEC of ORF2 mAb (9-7)

admin6th March 2020 at 4:15pm

Aim: Remove high molecular weight contaminants in his anti-ORF2 monoclonal antibody prep.

Materials:

Superose 200 increase 10/300 GL column (GE): 10kDa → 600 kDa separation range buffer: 1 x PBS Loaded 500 uL Flow rate: 0.25 mL/min

Fig. 1: Elution of protein standards on Superose200 increase 10/300 GL (GE)

Numbers correspond to the following MWs:

1: Thyroglobulin 669 kDa

2: Ferritin 440 kDa

3: Aldolase 158 kDa

4: Conalbumin 75 kDa

5: Ovalbumin 44 kDa

6: Carbonic anhydrase 29 kDa

7: Ribonuclease A 13.7 kDa

Results

Fig.2 FPLC trace of anti-ORF2 monoclonal antibody separation

● Peak is ~13 mL

● Eluting at roughly the same size as Aldolase (158 kDa)

● Some tapering, could be due to column interactions or heterogeneity of PTM’s on antibody.

Fig 3: SDS-PAGE of SEC fractions

Lanes: 1. MW marker (precision plus all blue, Bio-Rad, from Hua)

2. BSA 10 uL

3. BSA 15 uL

4. anti-ORF2 pre SEC

5. Fraction 2

6. Fraction 9

7. Fraction 10

8. Fraction 11

9. Fraction 12

10. Fraction 13

11. Fraction 14

12. Fraction 15

13. Fraction 16

14. Fraction 17

15. Fraction 18

● Fractions 12 - 16 contain protein (peak fractions 13 and 14) = in agreement with FPLC trace.

● 3 bands? Usually there’s a heavy chain at 50 kDa and a light chain at 25 kDa.

02/19/20 Concentrate purified anti-ORF2 antibody before making beads

Fractions 13 and 14, put tubes in speed vac, reduce the vol. from ~450 to 150ul each and combine

Fractions 9, 12, 13 (~1500ul total), combine, reduce vol to 600ul total in speed vac; split into 2 tubes (2x 300ul); add 100ul of 4M AmSO4, pH7.4 to each tube; put the tube back into the speed vol, reduce the vol to 150ul/tube (final AmSO4 is ~2.7M); Spin @ top speed for 10’; transfer the supernatant to different tube, resuspend the pellet in total of 100ul of 0.1M NaPhosphate, pH7.4

Make anti-ORF2 beads Date: Feb. 19, 2020

Combine all fractions and determine the concentration by Bradford Assay

Purified anti-ORF2: concentration 0.74mg/ml, total vol. 400ul (296ug total, use it to make 30mg of beads; ~10ug per mg of beads)

Recovered anti-ORF2 from previous conjugation (02/12/20): concentration 0.64mg, total vol. 300ul (192ug total, use it to make 20mg of beads; ~10ug per mg of beads)

Conjugation condition: 10ug of antibody per mg of beads; 20ul of antibody mix per mg of beads, 37°C overnight with mixing (24h total)

Wash beads with standard protocol

Store the beads in 50% glycerol/ 1xPBS / 0.5mg/ml BSA @ -20°C

Test anti-ORF2 beads Date: Feb. 20, 2020

Cell line: LD401 heavy_05/02/14

Extraction/wash buffer: 20mM HEPES, pH7.4, 500mM NaCl, 0.5% Triton X-100

Weigh out powder in 150mg LD401 heavy, add 600ul of extraction buffer, vortex to mix

2 Amp, 5x 2 sec (~20J total output); Operate in the cold room

Spin @ 20k rcf, 4°C for 10’ (Eppendorf Centrifuge 5417R)

Split the clarified lysate evenly into 3 aliquots (50mg each) and set up IP with 5ul of anti-ORF2 beads (from 3 different batches)

1) LD401_anti-ORF2_Old_091719

2) LD401_anti-ORF2_022020a

3) LD401_anti-ORF2_022020b

IP@ 4°C for 30’ After IP, wash 3x 1ml extraction buffer

Elute with 15ul of 1x LDS, 70°C for 5’ with shaking

Collect LDS elution

Add 50mM DTT (final conc.)

Heat samples @ 75°C for 10’

Run elution on 4-12% Bis-Tris gels

1) Marker

2) E1

3) E2

4) E3

5) Marker

6) Ab mix_pre coupling_2ul_purified

7) Ab mix_post coupling_2ul_purified

8) Ab mix_pre coupling_2ul_recovered

9) Ab mix_post coupling_2ul_recovered

10) BSA_50ng

11) BSA_150ng

12) Marker

13) 1ul anti-ORF2 (9-7) purified by Nat before concentrating (Fract.13)

14) 1ul anti-ORF2 (9-7) purified by Nat after concentrating (all combined)

15) 1ul anti-ORF2 (9-7) recovered from AbMix

Beads made on Feb. 19 (both from purified antibody or recovered antibody) seem to perform better than older batch. Will repeat anti-ORF2 IP with anti-FLAG IP as a control, make sure the difference we see here is not due to pipeting error of anti-ORF2 beads from different batches.